SEC Filings
IQVIA Cuts Trial Backlog By $2.1 Billion, Then Refinances 5.0% Notes With 6.375% Debt
The clinical research firm's backlog fell to $32.6 billion after it dropped inactive trials, while new 2034 notes carry a higher coupon.
IQVIA Holdings (IQV) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The clinical research firm's backlog fell to $32.6 billion after it dropped inactive trials, while new 2034 notes carry a higher coupon.
Earnings
CEO Ari Bousbib calls AI an added revenue stream in commercial work and a timeline-cutter in trials, not a reason to renegotiate rates.
Earnings
Ari Bousbib said large drugmakers reopened their outsourcing deals, and he expects the damage to smaller research firms to show within two or three years.
SEC Filings
The research-services company also trimmed its backlog estimate by about $2.1 billion and set a December 1 Investor Day.